Chronic combination therapy of amylin and GLP 1R analogs results in Download Scientific Diagram Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed